Base de dados : LILACS
Pesquisa : D04.210.500.365.415.331 [Categoria DeCS]
Referências encontradas : 53 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 53 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Id: lil-661214
Autor: Bruno, Ricardo Vasconcellos.
Título: Tratamento da atrofia urogenital com a administração local de estrogênios: um estudo randomizado, controlado em mulheres no climatério e na pós-menopausa / Treatment of urogenital atrophy with the local administration of oestrogens: a randomized, controlled study in climateric and postmenopausal women
Fonte: RBM rev. bras. med;69(8/9), ago.-set. 2012.
Idioma: pt.
Resumo: Objetivo: Avaliar a eficácia, segurança e aceitabilidade de cremes vaginais contendo promestriene (Colpotrofine®, Laboratórios Teva do Brasil) ou estriol (Ovestrion®, MSD, Brasil), em mulheres no climatério e na menopausa. Método: Estudo prospectivo, randomizado, aberto, de grupos paralelos e controlado. Locais: Instituto de Ginecologia da Universidade Federal do Rio de Janeiro e Faculdade de Medicina da Valença. Material: 80 mulheres na menopausa ou climatério, para quem o tratamento com creme vaginal de estrogênio foi indicado. Intervenção(s): As pacientes aplicaram 1g do creme vaginal, respectivo, a cada noite por 20 dias e depois uma aplicação semanal durante seis meses consecutivos. As pacientes foram distribuídas aleatoriamente sucessivamente numa proporção de 1:1, de acordo com a sua ordem de chegada: as pacientes ímpares foram designadas para receber promestriene e as com números pares foram designadas para receber estriol. Principal medida de desfecho(s): A variável de resposta primária foi a maturação do epitélio vaginal, avaliada pela citologia vaginal e medida pelo índice de Frost. Ambos os tratamentos melhoraram significativamente o trofismo do epitélio vaginal. Resultado(s): Uma melhoria acentuada (94,1%) foi indicado para pacientes do grupo promestriene por três meses, culminando na melhoria de 100% em 6 meses (p <0,0001). Houve clara melhoria dos sintomas da menopausa para ambos os grupos, sendo os tratamentos seguros e bem tolerados. Pacientes do grupo promestriene foram significativamente (p <0,038) mais satisfeitas (100%) com seu tratamento em comparação ao grupo estriol (73,33%). Conclusão(s): Ambos os tratamentos reverteram a atrofia vaginal, levando a um epitélio vaginal saudável, com destaque estatisticamente significativo para o promestriene, o que condicionou a uma melhoria da qualidade de vida.
Descritores: Climatério/metabolismo
Ensaios Clínicos Controlados Aleatórios como Assunto
Estriol/uso terapêutico
Pós-Menopausa/metabolismo
Limites: Seres Humanos
Feminino
Meia-Idade
Responsável: BR12.1 - Biblioteca Setorial da Ciências da Saúde


  2 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-949795
Autor: Ferreira, Aldo P.
Título: Distribución de esteroides estrogénicos en plantas de tratamiento de aguas residuales municipales / Distribution of estrogenic steroids in municipal wastewater treatment plants
Fonte: Acta toxicol. argent;25(3):80-90, dic. 2017. ilus, tab.
Idioma: es.
Resumo: En la actualidad, existe una preocupación creciente por la presencia de estrógenos en el medio acuático, donde pueden ser introducidos a partir de aguas residuales después de su eliminación incompleta en las plantas de tratamiento. Las aguas residuales sistemáticamente reciben estrógenos naturales y sintéticos, y por lo tanto una comprensión más profunda de la suerte de ellos en el medio ambiente es necesaria. Se evaluaron los niveles de estrógenos en los efluentes de las Plantas de Tratamiento de Aguas Residuales (PTARs) Penha e Ilha do Governador, ambos de tipo convencional de flujo continuo de lodo activado con aireación prolongada. Fue utilizado como el parámetro de determinación de algunos compuestos de interés como estrógenos naturales [estrona (E1), 17β-estradiol (E2), estriol (E3)) y sintéticos (17α-etinilestradiol (EE2)]. Las muestras individuales se recogieron posteriormente al tratamiento de cada PTAR y después de los procedimientos de laboratorio se realizó la determinación de estrógenos basado en la extracción en fase sólida (SPE) y la cromatografía líquida de alta resolución con detector de arreglo de diodos (HPLC-DAD). Las concentraciones fueron de: 0,7 a 5,2 μg/l y de 0,5 a 5,6 de E1; 0,9 a 7,7 y 1,2 a 9,2 μg/l para E2; 2,01 a 6,09 y 1,07 a 4,08 μg/l para EE2 en PTAR Penha y PTAR Ilha do Governador, respectivamente. La capacidad de eliminación de estrógenos fue eficaz, pero denota que la eliminación sistemática de la población es en la actualidad alta. Se recomienda instalar mecanismos para mitigar el consumo exagerado de estas sustancias o implementar una eliminación completa más eficaz.

Currently, there is a growing concern over the presence of estrogens in the aquatic environment, where they can be introduced from wastewater after their incomplete elimination in the treatment plants. Wastewater systematically receives natural and synthetic estrogens, and thus a deeper understanding of the fate of them in the environment is extremely necessary. It was evaluated estrogen levels in the effluent from the Sludge Wastewater Treatment Plants (SWTPs) Penha and Ilha do Governador, both of type conventional continuous-flow activated sludge with extended aeration. The determination of some target compounds as natural estrogens was used as the evaluation parameter [estrone (E1), 17β-estradiol (E2), estriol (E3) and synthetic (17α-ethinylestradiol (EE2)]. Individual samples were collected posterior treatment of each SWTP, and after laboratory procedures, the determination of estrogens was performed by a method based on solid phase extraction (SPE) and high performance liquid chromatography-diode array detector (HPLC-DAD). Concentrations ranged from 0.7 to 5.2 μg/l and from 0.5 to 5.6 for E1; 0.9 to 7.7 and 1.2 to 9.2 μg/l for E2; 2.1 to 6.9 and 1.7 to 4.8 μg/l for EE2 at SWTPs Penha and Ilha do Governador, respectively. The removal capacity of estrogens despite its effectiveness denotes that the systematic elimination by the population is high nowadays and urging mechanisms to mitigate the exaggerated consumption or to implement most effective complete removal.
Descritores: Esgotos/análise
Brasil/epidemiologia
Plantas de Tratamento de Águas Residuais/análise
Meio Ambiente
Estradiol/efeitos adversos
Estriol/efeitos adversos
Estrogênios/efeitos adversos
Estrona/efeitos adversos
Etinilestradiol/efeitos adversos
-Tratamento de Águas Residuárias/análise
Responsável: AR658.1 - Biblioteca Central "Leopoldo Marechal"


  3 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-735854
Autor: Gao, W.L.; Wu, L.S.; Zi, J.H.; Wu, B.; Li, Y.Z.; Song, Y.C.; Cai, D.Z..
Título: Measurement of serum estrogen and estrogen metabolites in pre- and postmenopausal women with osteoarthritis using high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;48(2):146-153, 02/2015. tab, graf.
Idioma: en.
Projeto: the Excellent Young Scientist Research Award fund of Shandong China; . the Medical and Health Science and Technology Development Plan of Shandong China; . and the development projects of Shandong Province Science and Technology of Traditional Chinese Medicine.
Resumo: Although 17β-estradiol (E2) deficiency has been linked to the development of osteoarthritis (OA) in middle-aged women, there are few studies relating other estrogens and estrogen metabolites (EMs) to this condition. We developed a high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (HPLC-ESI-MS/MS) method to measure the levels of six EMs (i.e., estrone, E2, estriol, 2-hydroxyestrone, 2-hydroxyestradiol, and 16a-hydroxyestrone) in healthy pre- and postmenopausal women and women with OA. This method had a precision ranging from 1.1 to 3.1% and a detection limit ranging from 10 to 15 pg. Compared to healthy women, serum-free E2 was lower in the luteal and postmenopausal phases in women with OA, and total serum E2 was lower in postmenopausal women with OA. Moreover, compared to healthy women, total serum 2-hydroxyestradiol was higher in postmenopausal women with OA and total serum 2-hydroxyestrone was lower in both the luteal and follicular phases in women with OA. In conclusion, our HPLC-ESI-MS/MS method allowed the measurement of multiple biochemical targets in a single assay, and, given its increased cost-effectiveness, simplicity, and speed relative to previous methods, this method is suitable for clinical studies.
Descritores: Cromatografia Líquida de Alta Pressão/métodos
Estrogênios/sangue
Osteoartrite/sangue
Pós-Menopausa/sangue
Pré-Menopausa/sangue
Espectrometria de Massas por Ionização por Electrospray/métodos
-Estradiol/análogos & derivados
Estradiol/sangue
Estriol/sangue
Estrogênios/metabolismo
Estrona/sangue
Fase Folicular/sangue
Hidroxiestronas/sangue
Limite de Detecção
Fase Luteal/sangue
Osteoartrite/metabolismo
Pós-Menopausa/metabolismo
Pré-Menopausa/metabolismo
Estatísticas não Paramétricas
Limites: Adulto
Idoso
Feminino
Seres Humanos
Meia-Idade
Tipo de Publ: Estudo Comparativo
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  4 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-701384
Autor: Botelho, Marco Antonio; Queiroz, Dinalva Brito; Barros, Gisele; Guerreiro, Stela; Fechine, Pierre; Umbelino, Sonia; Lyra, Arao; Borges, Boniek; Freitas, Allan; Queiroz, Danilo Caldas de; Ruela, Ronaldo; Almeida, Jackson Guedes; Quintans Jr., Lucindo.
Título: Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study
Fonte: Clinics;69(2):75-82, 2/2014. tab, graf.
Idioma: en.
Projeto: CNPq; . CNPq; . CNPq.
Resumo: OBJECTIVE: To determine the safety and efficacy of a transdermal nanostructured formulation of progesterone (10%) combined with estriol (0.1%) + estradiol (0.25%) for relieving postmenopausal symptoms. METHODS: A total of 66 postmenopausal Brazilian women with climacteric symptoms of natural menopause received transdermal nanostructured formulations of progesterone and estrogens in the forearm daily for 60 months to mimic the normal ovarian secretory pattern. Confocal Raman spectroscopy of hormones in skin layers was performed. Clinical parameters, serum concentrations of estradiol and follicle-stimulating hormone, blood pressure, BI-RADS classification from bilateral mammography, and symptomatic relief were compared between baseline and 60 months post-treatment. Clinicaltrials.gov: NCT02033512. RESULTS: An improvement in climacteric symptoms was reported in 92.5% of women evaluated before and after 60 months of treatment. The serum concentrations of estradiol and follicle-stimulating hormone changed significantly (p<0.05) after treatment; the values of serum follicle-stimulating hormone decreased after 60 months from 82.04±4.9 to 57.12±4.1 IU/mL. A bilateral mammography assessment of the breasts revealed normal results in all women. No adverse health-related events were attributed to this hormone replacement therapy protocol. CONCLUSION: The nanostructured formulation is safe and effective in re-establishing optimal serum levels of estradiol and follicle-stimulating hormone and relieving the symptoms of menopause. This transdermal hormone replacement therapy may alleviate climacteric symptoms in postmenopausal women. .
Descritores: Estradiol/uso terapêutico
Estriol/uso terapêutico
Estrogênios/uso terapêutico
Terapia de Reposição Hormonal/métodos
Pós-Menopausa/efeitos dos fármacos
Progesterona/uso terapêutico
-Administração Cutânea
Combinação de Medicamentos
Estradiol/sangue
Hormônio Foliculoestimulante/sangue
Microscopia Eletrônica de Varredura
Tamanho da Partícula
Estudos Prospectivos
Pós-Menopausa/fisiologia
Análise Espectral Raman
Pele/efeitos dos fármacos
Fatores de Tempo
Resultado do Tratamento
Limites: Idoso
Feminino
Seres Humanos
Meia-Idade
Tipo de Publ: Ensaio Clínico
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  5 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-665800
Autor: Brazilian Journal of Medical and Biological Research; Konopka, C.K.; Morais, E.N.; Naidon, D.; Pereira, A.M.; Rubin, M.A.; Oliveira, J.F.; Mello, C.F..
Título: Maternal serum progesterone, estradiol and estriol levels in successful dinoprostone-induced labor
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;46(1):91-97, 11/jan. 2013. tab, graf.
Idioma: en.
Projeto: CNPq.
Resumo: Hormone-mediated quiescence involves the maintenance of a decreased inflammatory responsiveness. However, no study has investigated whether labor induction with prostanoids is associated with changes in the levels of maternal serum hormones. The objective of this study was to determine whether labor induction with dinoprostone is associated with changes in maternal serum progesterone, estradiol, and estriol levels. Blood samples were obtained from 81 pregnant women at term. Sixteen patients had vaginal birth after spontaneous labor, 12 required cesarean section after spontaneous labor and 16 underwent elective cesarean. Thirty-seven patients had labor induction with dinoprostone. Eligible patients received a vaginal insert of dinoprostone (10 mg) and were followed until delivery. Serum progesterone (P4), estradiol (E2) and estriol (E3) levels and changes in P4/E2, P4/E3 and E3/E2 ratios were monitored from admission to immediately before birth, and the association of these measures with the resulting clinical classification outcome (route of delivery and induction responsiveness) was assessed. Progesterone levels decreased from admission to birth in patients who underwent successful labor induction with dinoprostone [vaginal and cesarean birth after induced labor: 23% (P < 0.001) and 18% (P < 0.025) decrease, respectively], but not in those whose induction failed (6.4% decrease, P > 0.05). Estriol and estradiol levels, P4/E2, P4/E3 and E3/E2 ratios did not differ between groups. Successful dinoprostone-induced labor was associated with reduced maternal progesterone levels from induction to birth. While a causal relationship between progesterone decrease and effective dinoprostone-induced labor cannot be established, it is tempting to propose that dinoprostone may contribute to progesterone withdrawal and favor labor induction in humans.
Descritores: Dinoprostona
Estradiol/sangue
Estriol/sangue
Trabalho de Parto Induzido/métodos
Ocitócicos
Progesterona/sangue
-Resultado da Gravidez
Nascimento a Termo/sangue
Limites: Adulto
Feminino
Seres Humanos
Recém-Nascido
Gravidez
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  6 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-610321
Autor: Villaseca D., Paulina.
Título: Atrofia urogenital: seguridad del tratamiento con estrógenos vaginales / Safety of vaginal estrogens for urogenital atrophy
Fonte: Rev. chil. endocrinol. diabetes;3(3):208-210, jul. 2010.
Idioma: es.
Resumo: Urogenital atrophy is characterized by dryness, inflammation, and thinning of the epithelial lining of the vagina and lower urinary tract due to estrogen decline. Local estrogen therapy if effective to relieve signs and symptoms of vaginal atrophy without causing an elevation of serum estrogen levels. Although there are no big studies addressing the safety of this type of treatment, it can be maintained over long periods to avoid annoying symptoms. Special care must be taken with women with breast cancer in whom the effective dose must be titrated to avoid an increase in serum estrogens over the levels usually observed in postmenopausal women.
Descritores: Doenças Urogenitais Femininas/tratamento farmacológico
Estradiol/administração & dosagem
Estriol/administração & dosagem
Estrogênios/administração & dosagem
-Administração Intravaginal
Atrofia/tratamento farmacológico
Neoplasias da Mama
Climatério
Pomadas
Comprimidos
Cremes, Espumas e Géis Vaginais
Vagina
Vagina/patologia
Limites: Seres Humanos
Feminino
Responsável: CL1.1 - Biblioteca Central


  7 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-609579
Autor: Ángeles-Palacios, Reyna; Bacalla, Leidy; Campos, Karen; Cusihuamán, Yuly; Osorio, Milagros; Flores, Daisy.
Título: Efecto antinociceptivo de estriol y Glicina max l. (soya) en ratas ovariectomizadas / Antinociceptive effect of estriol and Glicina max l. (soya) in ovariectomized rats
Fonte: An. Fac. Med. (Perú);72(1):17-22, ene.-mar. 2011. tab, graf.
Idioma: es.
Resumo: Objetivo: Demostrar el efecto protector del estriol y Glicina max L. (soya) frente al dolor nociceptivo, en ratas ovariectomizadas. Diseño: Estudio experimental. Lugar: Bioterio de la Facultad de Medicina, Universidad Nacional Mayor de San Marcos. Material biológico: Ratas hembras albinas Holtzman de 2,5 a 3 meses de edad. Métodos: Las 29 ratas fueron agrupadas aleatoriamente: grupo 1 (n=8), no ovariectomizadas, tratadas con solución salina (0,1 mL/kg); grupo 2 (n=7), ovariectomizadas y tratadas con solución salina (0,1 mL/kg); grupo 3 (n=7), ovariectomizadas y tratadas con estriol (0,2 mg/kg); grupo 4 (n=7), ovariectomizadas y tratadas con Glycine max L. (60 mg/kg). Se realizó una prueba basal de dolor térmico en el hornillo a todos los animales, así como tres días después del tratamiento farmacológico. Principales medidas de resultados: Se usó el porcentaje de eficiencia antinociceptiva máxima (porcentaje EAM). Resultados: Se encontró que el porcentaje EAM fue mayor en el grupo de ratas no ovariectomizadas (1,6 por ciento) que en el grupo de las ovariectomizadas (0,8 por ciento). Por otro lado, el porcentaje EAM en ratas ovariectomizadas con solución salina (0,8 por ciento) fue menor al compararlo con el grupo de las tratadas con estriol (5,8 por ciento); así también, el porcentaje EAM del grupo de ovariectomizadas tratadas con Glicina max L. (4,2 por ciento) fue superior al grupo de ovariectomizadas tratadas con solución salina (0,8 por ciento), pero esta no fue superior a las del grupo tratadas con estriol. Conclusiones: El estriol y la Glicina max L. ejercieron un papel protector frente al dolor nociceptivo térmico en ratas ovariectomizadas.

Objective: To determine the protective effect of estriol and Glycine max L. (soybean) compared to nociceptive pain in ovariectomized rats. Design: Experimental study. Setting: Faculty of Medicine bioterium, Universidad Nacional Mayor de San Marcos, Lima, Peru. Biological material: Holtzman albino female rats 2,5 to 3 months of age. Methods: The 29 rats were grouped randomly: group 1 (n = 8) non ovariectomized rats treated with saline (0.1 mL/kg); group 2 (n = 7) ovariectomized rats treated with saline (0.1 mL / kg); group 3 (n = 7) ovariectomized rats treated with estriol (0.2 mg/kg); group 4 (n = 7) ovariectomized rats treated with Glycine max L. (60 mg/kg). We determined baseline hotplate thermal pain as well as three days after treatment. Main outcome measures: Antinociceptive maximum efficacy (percentage AME). Results: We found that percentage EAM was higher in the non ovariectomized rats group (1.6 per cent) than in the ovariectomized group (0.8 per cent). Furthermore, the percentage of EAM in ovariectomized rats treated with saline (0.8 per cent) compared with the group treated with estriol (5.8 per cent) and also the percentage of EAM in the Glycine max L. group (4.2 per cent) was higher than in the ovariectomized group treated with saline (0.8 per cent) but not higher than the group treated with estriol. Conclusions: Estriol and Glycine max L. have protective role against thermal nociceptive pain in ovariectomized rats.
Descritores: Estriol
Glicinérgicos
Ovariectomia
Dor
-Epidemiologia Experimental
Limites: Animais
Feminino
Ratos
Responsável: PE13.1 - Oficina de Biblioteca, Hemeroteca y Centro de Documentación


  8 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-595041
Autor: Vorster, Chris; Joubert, Annie.
Título: In vitro effects of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line
Fonte: Biocell;34(2):71-79, Aug. 2010. ilus, graf.
Idioma: en.
Resumo: In the search for new and improved anticancer therapies, researchers have identified several potentially useful compounds. One of these agents is 2-methoxyestradiol-bis-sulphamate (2ME-BM), a sulphamoylated derivative of 2-methoxyestradiol. The objective of this study was to evaluate 2ME-BM's in vitro efficacy as antiproliferative agent in the MCF-7 breast adenocarcinoma cell line. Light- and fluorescent microscopy showed decreased cell density, increased apoptotic characteristics and significant ultrastructural aberrations indicative of autophagic cell death after 24 hours of exposure at a concentration of 0.4 microM. In addition, mitotic indices revealed that 2ME-BM induces a G2M block. The latter was confirmed by flow cytometric analyses where increased sub-G1 and G2/M fractions, as well as an increase in cycli n B1 levels were observed. Further in vitro research into the mechanism of this potentially useful anticancer compound is thus warranted.
Descritores: Ciclo Celular
Estriol/análogos & derivados
Estriol/farmacologia
Estriol/química
Linhagem Celular Tumoral
Linhagem Celular Tumoral/ultraestrutura
Proliferação Celular
-Neoplasias da Mama
Estrutura Molecular
Limites: Seres Humanos
Feminino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: AR40.1 - Biblioteca de la Facultad de Ciencias Médicas de la UNCuyo


  9 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-595012
Autor: Mqoco, Thandi; Marais, Sumari; Joubert, Annie.
Título: Influence of estradiol analogue on cell growth, morphology and death in esophageal carcinoma cells
Fonte: Biocell;34(3):113-120, Dec. 2010. ilus, graf.
Idioma: en.
Resumo: 2-Methoxyestradiol-bis-sulphamate is a bis-sulphamoylated derivative of the naturally occurring 17-beta-estradiol metabolite namely 2-methoxyestradiol. 2-Methoxyestradiol-bis-sulphamate is regarded as a potential anticancer drug with increased antiproliferative activity when compared to 2-methoxyestradiol. The aim of this pilot in vitro study was to determine the influence of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and possible induction of certain types of cell death in the SNO esophageal carcinoma cell line. A dose-dependent study (0.2-1.0 microM) was conducted with an exposure time of 24 hours. Data revealed that 2-methoxyestradiol-bis-sulphamate reduced cell numbers statistically significantly to 74% after exposure to 0.4 microM of the drug. Morphological studies including light microscopy demonstrated hallmarks of apoptosis, while fluorescent microscopy revealed both the presence of apoptosis and autophagy as types of cell death being induced in SNO cells after 24 hours of exposure to 0.4 microM 2-methoxyestradiol-bis-sulphamate.
Descritores: Apoptose
Autofagia
Contagem de Células
Carcinoma de Células Escamosas/patologia
Ciclo Celular
Divisão Celular
-Linhagem Celular Tumoral
Relação Dose-Resposta a Droga
Estriol/análogos & derivados
Estriol/farmacologia
Neoplasias Esofágicas/patologia
Limites: Seres Humanos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: AR40.1 - Biblioteca de la Facultad de Ciencias Médicas de la UNCuyo


  10 / 53 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-528107
Autor: Bryś, Magdalena; Szytto, Krzysztof; Romanowicz-Makowska, Hanna; Dobrowolski, Zbigniew; Mastowska, Izabela; Krajewska, Wanda.
Título: Expression of estrogen and progesterone receptor genes in endometrium, myometrium and vagina of postmenopausal women treated with estriol / Expresión de los genes receptores de estrógeno y progesterona en el endometrio, miometrio y vagina en mujeres posmenopáusicas tratadas con estriol
Fonte: Säo Paulo med. j;127(3):128-133, 2009. ilus, tab.
Idioma: en.
Resumo: CONTEXT AND OBJECTIVE: Estriol is an estrogen with considerably weaker stimulatory effects on endometrial proliferation than estradiol. A study was conducted to determine the level of estrogen receptors (ERs) and progesterone receptors (PRs) in women who received 14-day vaginal estriol therapy, compared with those who did not receive this therapy. ER and PR gene expression was analyzed in the endometrium, myometrium and vagina of postmenopausal women treated with estriol. DESIGN AND SETTING: Analytical cross-sectional study, at the Research Institute of the Polish Mothers' Memorial Hospital, Lodz, Poland. METHODS: Twenty-seven postmenopausal women (57-74 years of age) were included in the study. All of them were waiting for per vaginam hysterectomy or plastic surgery on the vagina and perineum because of uterine prolapse. ER and PR gene expression was determined by means of the technique of reverse transcription polymerase chain reaction (RT-PCR). RESULTS: In the estriol-treated patients, in comparison with the control group, a significant increase in ER gene expression was observed in the endometrium and vagina, while enhanced PR gene expression was found in the endometrium. However, under histological examination of the endometrium, estrogen stimulation of low and medium degree was diagnosed for 21.4 percent and 14.3 percent of the estriol-treated women, respectively. CONCLUSION: The results obtained suggest that the women who received 14 days of treatment with vaginal estriol had higher ER and PR mRNA levels. No difference between these groups regarding endometrial proliferation was observed.

CONTEXTO Y OBJETIVO: El estriol es un estrógeno con un efecto estimulatorio bastante más débil sobre la proliferación endometrial que el estradiol. Se realizó un estudio para determinar los efectos de una terapia vaginal de 14 días con estriol, sobre el nivel de receptores de estrógeno (ER) y receptores de progesterona (PR), comparado con mujeres sin esa terapia. La expresión de los genes de ER y PR se analizó en el endometrio, miometrio y vagina de mujeres posmenopáusicas tratadas con estriol. DISEÑO Y UBICACIÓN: Estudio Transversal analítico, en el Instituto de Investigación del Hospital de la Madre Polaca en Lodz, Polonia. MÉTODOS: Se incluyeron veintisiete mujeres posmenopáusicas (de 57 a 74 años) en el estudio. Todas ellas estaban en espera de una histerectomía per vaginam o de cirugía plástica de la vagina y del perineo debido a un prolapso del útero. La expresión de genes de los receptores ER y PR se estableció por la técnica de RT-PCR. RESULTS: En las pacientes tratadas con estriol en comparación con el grupo de control, se observó un aumento significativo de la expresión del gen de ER en el endometrio y la vagina, mientras que un aumento de la expresión del gen de PR se encontró en el endometrio. De todas formas, en el examen histológico del endometrio, se diagnosticó estimulación estrogénica de bajo y medio grado en el 21.4 por ciento y en el 14.3 por ciento de las mujeres tratadas con estriol, respectivamente. CONCLUSIONES: Los resultados obtenidos sugieren que un tratamiento de 14 días con estriol en pacientes, aunque aumentan el nivel de ER y de PR mRNA, tiene muy poco o ningún efecto sobre la proliferación endometrial.
Descritores: Endométrio/metabolismo
Estriol/uso terapêutico
Miométrio/metabolismo
Pós-Menopausa/metabolismo
Receptores Estrogênicos/genética
Receptores de Progesterona/genética
Vagina/metabolismo
-Estudos Transversais
Expressão Gênica/efeitos dos fármacos
Pós-Menopausa/efeitos dos fármacos
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Receptores Estrogênicos/metabolismo
Receptores de Progesterona/metabolismo
Limites: Idoso
Feminino
Seres Humanos
Meia-Idade
Tipo de Publ: Ensaio Clínico Controlado
Responsável: BR1.1 - BIREME



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde